Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
The Daily Target 2X Short LLY ETF (LLYZ) is designed to provide investors with two times the inverse daily performance of the stock of Eli Lilly and Company (LLY). This ETF is particularly sensitive to movements in LLY's stock price, making it a tool for investors looking to hedge against or profit from declines in Eli Lilly's market performance, especially in the biopharmaceutical sector where LLY operates.
LLYZ generates revenue primarily through management fees associated with ETF operations. The fund's performance is directly tied to the inverse movements of Eli Lilly's stock price, allowing it to capitalize on short-term declines in LLY's value. This model benefits from high liquidity and trading volumes, which can enhance fee income.
Eli Lilly's stock price fluctuations, particularly related to drug approvals and clinical trial results
Market sentiment regarding the biopharmaceutical sector
Changes in healthcare regulations affecting pharmaceutical pricing
Broader market trends impacting investor sentiment towards biotech stocks
Regulatory changes in the pharmaceutical industry that could impact drug pricing and approval processes
Technological advancements that may disrupt traditional pharmaceutical business models
Increased competition from generic drug manufacturers and biosimilars
Emerging biotech firms with innovative therapies that could capture market share from Eli Lilly
LLY's debt levels could impact its stock performance if not managed effectively
Potential liabilities from litigation or regulatory fines affecting investor sentiment
moderate - The performance of LLYZ is somewhat linked to the overall economic cycle, as healthcare spending can be influenced by economic conditions.
Interest rates can affect the cost of capital for Eli Lilly, influencing its stock price and, consequently, LLYZ's performance. Higher rates may lead to reduced investment in biotech and pharmaceuticals.
minimal - The ETF does not have significant credit exposure as it does not rely on debt financing.
momentum - Investors looking to capitalize on short-term declines in Eli Lilly's stock price would find this ETF appealing.
high - The ETF is likely to exhibit high volatility due to its leveraged nature and sensitivity to LLY's stock price.